Analyst Ratings for Editas Medicine (EDIT)

EDIT Rating Summary

EDIT Price Target Summary

* Over Last 12-Mos
  |   Expand Research on EDIT
Overall Rating: NEUTRAL   Rating Trend: Down   Avg. $ Target: $7.23 (+207.6%) * Over Last 12-Mos
Rating Score: 4.6 / 10   Percentile Rank: 46%
Date Firm Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
10/8/2026 Wells Fargo Yanan Zhu Upgrade Equal Weight
(Underweight)		 6.00
(4.00)		 2.75
(2.35)		 -14.55% Details
9/23/2026 Guggenheim Debjit Chattopadhyay Upgrade Buy
(Neutral)		 5.00
(N/A)		 2.93
(2.35)		 -19.8% Details